BGBIO: BerGenBio Third Quarter Results 2024
Bergen, Norway, November 13, 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharma-ceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced financial results for the quarter
and half year ended September 30, 2024, and provided a business update.
Highlights, including post period:
BGBC016 1L NSCLC STK11m Study
· Ph1b enrollment completed